Marking the start of 2013, MD247 announced that its "chat with a doctor" program would be available to both large and small businesses around Washington DC commencing 01/02/13.
Tampa, FL (PRWEB) January 02, 2013
Marking the start of 2013, MD247 announced that its "chat with a doctor" program would be available to both large and small businesses around Washington DC commencing 01/02/13. Telemedicine offers business owners the opportunity to provide supplemental healthcare to employees, without forcing a massive cut in the number of employees. The addition of the greater Washington DC area is one cog in the MD247 plan to offer employers viable options against the Affordable Healthcare Act.
The MD247 services provide telemedicine program members with the opportunity to conveniently remain either in the comfort of their own home, or otherwise engaged at work, while relaying their medical symptoms to a waiting staff of licensed medical professionals. 24/7 telemedicine is a fiscally sound, and culturally popular alternative which can either supplement or replace traditional bureaucracy burdened health insurance coverage. The MD247 telemedcine program is proving to be particularly attractive to families, who may have members that fall outside of typical health insurance policy coverage due to either age or a pre-existing condition.
Largo Florida based MD247.COM (MD247; MD/247; MD 247; M.D.247; MD-247) provides an affordable telemedicine supplement to existing healthcare services. MD247.COM telemedicine program members have unlimited telephone access to a nationwide medical support team, all with just a single phone call to the MD247.COM telemedicine Chat with a Doctor/Talk to a Nurse Hotline. MD247.COM has a virtual platoon of registered nurses; board certified physicians and a support staff available to members for all non-emergency situations. More information about MD247.COM is available online at http://www.md247.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/1/prweb10284545.htm
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.